Lilly and Banner Alzheimer’s Institute in strategic research collaboration for donanemab trial

By Rachel Arthur contact

- Last updated on GMT


Related tags: Alzheimer's disease, Monoclonal antibodies, Eli lilly and company

Eli Lilly and Company and Banner Alzheimer’s Institute have announced a strategic research collaboration as part of the planned Phase 3 study for donanemab in participants at risk from cognitive and functional decline related to Alzheimer’s disease.

The ‘TRAILBLAZER-ALZ 3’ trial will evaluate whether treatment with donanemab can slow the clincial progression of Alzheimer’s diseases in participants.

Donanemab is an investigational antibody that targets a modified form of beta amyloid called N3pG. Phase 2 data, published in March, showed the monoclonal antibody ‘met its primary endpoint and showed significant slowing of decline’​ in cognitive and daily function in patients with early symptomatic Alzheimer’s disease.

Enrolment in the Phase 3 trial is expected to begin later this year, with Lilly remaining the sole sponsor of the trial.

Formed in 2006, the Banner Alzheimer’s Institute's aims are to find effective Alzheimer’s disease prevention therapies and forge new models of collaboration in biomedical research. As part of the new collaboration announced today, Banner will contribute its expertise in prevention trials and support enrolment of trial participants with and without the e4 type of the apolipoprotein E (APOE4) gene through the Alzheimer's Prevention Registry's GeneMatch program.

Notably, the collaboration will introduce a more virtual approach to the evaluation of Alzheimer's prevention therapies.

"This study will provide a great deal of flexibility in how and where participants complete study visits,"​ Dr. Eric Reiman, Banner Alzheimer's Institute executive director and one of the study's lead principle investigators, told this publication.

"In a traditional study, participants go to a study site to conduct all study activities. In TRAILBLAZER-ALZ 3, participants have the option to conduct activities in a location of their choice (that is, using electronic tablets and video calls) that do not require in-person interactions, such as informed consent; collection of medical history and adverse events; cognitive and functional assessments; etc.

"For in-person activities, such as infusions, blood draws, imaging, and physical exams, participants may go to a traditional site or another “satellite” facility that provides these services. These facilities may include infusion centers, mobile research units, imaging centers, etc.

"Given that a large portion of study activities may be completed in the location of their choice, such as their own home, study partners do not even need to be in the same location as their study participant(s). We believe this approach increases opportunity for study participation for people who do not live near major medical centers that typically conduct clinical trials.

"We also anticipate that this flexibility could increase clinical trial participation for underrepresented populations."

Recruiting participants

Recruitment is one of the biggest obstacles researchers face for all Alzheimer’s-focused studies and this is only exacerbated in Alzheimer’s prevention trials.

"It is challenging to raise awareness that there are prevention trial opportunities, since most people don’t think of joining a clinical trial while they are healthy,"​ said Dr Reiman. "It is hard to find enough people willing to enter screening and who meet a trial’s specific eligibility criteria for enrollment."

To help address these challenges, Banner has developed programs like our Alzheimer’s Prevention Registry,​ and GeneMatch program​, which are similar to “matchmaking” services for research studies.

"These tools help engage, inform, and identify cognitively unimpaired people who may be interested in research. They also help diversify study participation, which is crucial to enroll participants who are representative of the population and people who may ultimately receive the treatment if a trial is successful and the treatment approved.

"The TRAILBLAZER-ALZ3 3 trial will capitalize on these programs and the use of a widely deployable blood test for Alzheimer’s disease (Lilly’s plasma p-tau217 assay) to reach out to participants where they live, and it will make it easier for them to participate in studies close to their home and in more convenient settings. We hope that this approach will help galvanize the enrollment of interested and eligible research participants in this prevention trial and set a precedent for other trials so that we can find effective Alzheimer’s prevention therapies as soon as possible."

Related news

Related products

show more

The APAC Advantages

The APAC Advantages

Catalent Pharma Solutions | 18-Jan-2022 | Insight Guide

Over recent years, the Asia-Pacific (APAC) region has become an emerging market for pharmaceutical and biotech innovation, including clinical studies.

CellCarta - Mapping Precision Medicine

CellCarta - Mapping Precision Medicine

CellCarta | 17-Jan-2022 | Product Presentation

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 17-Jan-2022 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 01-Nov-2021 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Related suppliers

Follow us


View more